POZEN’S PA8140/PA32540 Receives a Complete Response Letter From FDA Citing Issues at a Facility of a Third Party Supplier of an Active Ingredient

[Business Wire] – POZEN Inc. , a pharmaceutical company committed to transforming medicine that transforms lives, announced today that their drug candidates PA8140/PA32540 delayed release tablets have received a complete response letter from the U.S. more

View todays social media effects on POZN

View the latest stocks trending across Twitter. Click to view dashboard

See who Pozen is hiring next, click here to view